Sustained Therapeutics
June 24, 2026
Theater 2
Type: Company Presentation
Focus Area:
Pain Management
Sustained Therapeutics is developing a sustained-release drug delivery platform for localized delivery of drugs serving large unmet medical needs with significant market potential.
Its lead product (ST-01) is a non-opioid medication for the treatment of chronic pain. ST-01 was designed to deliver sustained non-opioid pain relief for about 28 days from a single injection. A phase 1 study was successful and GMP manufacturing has been completed. The Phase 2 study of ST-01 in chronic pain has also been successful. Results demonstrated that ST-01 was safe and effective, delivering clinically meaningful reductions in pain. The study met both its primary and secondary endpoints.
Based on these results, Sustained Therapeutics plans to proceed to Phase 3 trials in Canada and the United States, subject to regulatory approval.
The company has a strong management team with many years experience in the life sciences industry and in the development and launch of pharmaceutical products.
Company HQ City:
Vancouver
Company HQ State:
BC
Company HQ Country:
Canada
Year Founded:
2016
Lead Product in Development:
ST-01 non-opioid pain medication
CEO
William Annett
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
Three
When you expect your next catalyst update?
January 2027
What is your next catalyst (value inflection) update?
Initiation of Phase 3 trial of ST-01
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}